A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer



Status:Active, not recruiting
Conditions:Breast Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:45 - 100
Updated:4/21/2016
Start Date:February 2006
End Date:December 2016

Use our guide to learn which trials are right for you!

A Randomized, Open-Label, Parallel-Group, Multicentre, Phase II Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX™) 500 mg With Anastrozole (ARIMIDEX™) 1 mg as First Line Hormonal Treatment for Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer

The purpose of this study is to compare the efficacy and tolerability of Faslodex
(fulvestrant) with Arimidex (anastrozole) in postmenopausal women with hormone receptor
positive advanced breast cancer.


Inclusion Criteria:

- Confirmed hormone receptor positive advanced breast cancer, postmenopausal women

Exclusion Criteria:

- Previous treatment for advanced breast cancer (previous treatment for early breast
cancer is allowed).
We found this trial at
6
sites
?
mi
from
Frederick, MD
Click here to add this to my saved trials
?
mi
from
Austin, TX
Click here to add this to my saved trials
?
mi
from
Barretos,
Click here to add this to my saved trials
?
mi
from
Duncanville, TX
Click here to add this to my saved trials
?
mi
from
St. Louis, MO
Click here to add this to my saved trials
?
mi
from
Teaneck, NJ
Click here to add this to my saved trials